معرفی
Lars Lund is a Professor/Senior Physician at Karolinska Institutet's Department of Medicine, Solna, leading research on heart failure mechanisms and clinical management. He specializes in heart failure with reduced and preserved ejection fraction (HFrEF/HFpEF), focusing on translational research, clinical trials, and registry-based studies. His work bridges molecular biology, epidemiology, and clinical practice, aiming to improve treatment strategies and patient outcomes. Key affiliations include the Swedish Heart Failure Registry (SwedeHF) and leadership of the Heart Failure Research Group.
- Education: Economics (College of Charleston, USA), Medicine (Duke University), Molecular Biology PhD (Karolinska Institutet, 2005).
- Roles: Professor of Cardiology since 2018, Associate Professor (2011–2018), and clinical training at Columbia University and Karolinska University Hospital.
Research interests include new treatments for HFrEF, mechanisms of HFpEF, and optimization of guideline-directed therapy. His team investigates drug repurposing, biomarkers, and quality of life in heart failure patients. Notable grants include the Swedish Research Council-funded SPIRRIT-HFpEF trial and studies on inotropic therapies.
Recent publications emphasize clinical trial design, registry analyses, and therapeutic gaps in heart failure subtypes. He was recognized as a Clarivate Highly Cited Researcher in 2024 for impactful contributions to cardiology.
Advises over 10 PhD students and leads multi-institutional collaborations in Europe and globally. His lab focuses on translational research, bridging basic science and clinical application in heart failure management.